Tomasz Grzegorz Mazur

Mrs. Tomasz Grzegorz Mazur

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in Journal of Inorganic Biochemistry
Verified
Journal Article
Open access
TMTomasz Grzegorz Mazur
Tomasz Grzegorz Mazur
Magdalena RydzMagdalena Rydz
Magdalena Rydz
DBDariusz C. Bieńko
Dariusz C. Bieńko
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid - β extracellular plaques and tau interfibrillar tangles, leading to memory loss, cognitive decline, and behavioral changes. With dementia posing a growing global health concern, there is an urgent need for comprehensive strategies to address its challenges. The economic burden of dementia is projected to rise significantly, emphasizing the necessity for collaborative efforts in research and healthcare. In the United States alone, millions are affected by AD, with prevalence increasing with age and even affecting younger individuals. The complexity of AD involves intricate biological processes, including the aggregation of amyloid beta, oxidative stress, and metal ion dysregulation. Metal ions, particularly those from copper, iron, and zinc, play pivotal roles in AD pathology, influencing Aβ deposition and tau protein accumulation. Current treatments offer symptomatic relief but do not address the underlying disease mechanisms. This paper explores the potential of various chelating compounds to target metal ions involved in AD pathology. N-acylhydrazones, morpholine, chrysin, quinoline, oxindole, cyclam, catechol-based, and quinazolinone-based derivatives show promising chelation activity and therapeutic effects. Metal chelation therapy offers a targeted approach to AD treatment by addressing the core pathology. By selectively binding to metal ions implicated in disease progression, chelators may minimize side effects associated with broad-spectrum treatments. Additionally, chelators may offer neuroprotective effects beyond metal binding, further enhancing their therapeutic potential. Overall, metal chelation therapy presents a promising strategy in combating AD, with the potential to significantly impact disease progression and improve patient outcomes.

17 March 2026 in Molecules
Verified
Journal Article
Open access
PDF file
Magdalena RydzMagdalena Rydz
Magdalena Rydz
TMTomasz Grzegorz Mazur
Tomasz Grzegorz Mazur
Anna SwitlickaAnna Switlicka
Anna Switlicka
UKUrszula K. Komarnicka
Urszula K. Komarnicka
DWDaria Wojtala
Daria Wojtala
DBDariusz Bieńko
Dariusz Bieńko
Three new Mn(II) complexes with imidazo[1,2-a]pyridine derivatives were synthesized and structurally characterized in a solid state by single crystal X-ray diffraction, FT-IR and Raman spectroscopy, and thermal analyses. The investigated compounds include [Mn(3-Climpy)2Cl2(MeOH)2] (1), [Mn(3-Brimpy)2Cl2(MeOH)2] (2), and a rare double chloro-bridged coordination polymer [Mn(impy)2Cl2]n (3). Spectroscopic studies were used to assess their potential stability in DMEM (Dulbecco’s Modified Eagle Medium), and encapsulation in Pluronic P-123 micelles improved their solubility in aqueous solution, as well as cellular uptake and selectivity. Biological evaluation revealed negligible cytotoxicity against most cancer and control cell lines, but unexpectedly high activity against pancreatic adenocarcinoma (PANC-1), exceeding that of cisplatin. Complex 2, bearing a bromine substituent in the imidazole ring, showed the strongest effects, correlating with enhanced intracellular accumulation, reactive oxygen species (ROS) generation, and mitochondrial membrane potential disruption. Molecular docking and protein binding assays demonstrated moderate affinity toward human serum albumin (HSA) and transferrin, whereas DNA interaction was weak and non-damaging. These results highlight the structure–activity relationship of Mn(II) imidazo[1,2-a]pyridine complexes and support their potential as targeted redox-active agents against pancreatic cancer, with polymeric encapsulation providing an effective strategy to enhance biological performance.

16 November 2026 in ChemMedChem
Verified
Journal Article
Closed access
TMTomasz Grzegorz Mazur
Tomasz Grzegorz Mazur
MRMagdalena Rydz
Magdalena Rydz
BMBarbara Machura
Barbara Machura
KSKamila Sroda-Pomianek
Kamila Sroda-Pomianek
OWOlga Wesołowska
Olga Wesołowska
DBDariusz Bieńko
Dariusz Bieńko